A. Mühlemann

Comparison of the binding pockets of two chemically unrelated allosteric antagonists of the mGlu5 receptor and identification of crucial residues involved in the inverse agonism of MPEP

Martin Stahl, Andreas Mühlemann, P. Gerber, 2006, Journal of neurochemistry.

Fenobam: A Clinically Validated Nonbenzodiazepine Anxiolytic Is a Potent, Selective, and Noncompetitive mGlu5 Receptor Antagonist with Inverse Agonist Activity

Jens-Uwe Peters, Richard H. P. Porter, W. Spooren, 2005, Journal of Pharmacology and Experimental Therapeutics.

Constitutive activity modulation of human metabotropic glutamate 5a receptors in HEK293 cells: a role for key amino‐terminal cysteine residues

J. Piussi, C. Diener, Christophe Fischer, 2005, British journal of pharmacology.

Removal of razor blades from stomach with fibreoptic endoscope.

L. Witzel, F. Halter, A. Mühlemann, 1974, British medical journal.

Functional study of neuronal calcium sensor-1 (NCS-1) in yeast and mice : a role for NCS-1 in learning and memory

A. Mühlemann, 2005 .

Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types

O. Morand, N. Üçeyler, P. Groenen, 2018, Human molecular genetics.

An Automated System for the Analysis of G Protein-Coupled Receptor Transmembrane Binding Pockets: Alignment, Receptor-Based Pharmacophores, and Their Application

Martin Ebeling, Martin Stahl, Paul R. Gerber, 2005, J. Chem. Inf. Model..

Determination of key amino acids implicated in the actions of allosteric modulation by 3,3'-difluorobenzaldazine on rat mGlu5 receptors.

Andreas Mühlemann, P. Malherbe, N. Ward, 2006, European journal of pharmacology.

Lucerastat, an iminosugar for substrate reduction therapy in Fabry disease: preclinical evidence

D. Priestman, F. Platt, M. Iglarz, 2017 .